

Resource Summary Report

Generated by [dkNET](#) on Sep 20, 2026

NCI-H295R

RRID:CVCL_0458

Type: Cell Line

Proper Citation

RRID:CVCL_0458

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0458

Proper Citation: RRID:CVCL_0458

Description: Cell line NCI-H295R is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Adrenal cortex carcinoma

Defining Citation: [PMID:15541570](#), [PMID:18000308](#), [PMID:20215515](#), [PMID:21924324](#), [PMID:22266826](#), [PMID:23951072](#), [PMID:29371329](#), [PMID:33981288](#), [PMID:34572026](#), [PMID:35563746](#), [PMID:35764904](#)

Comments: Characteristics: Grows in a medium called Nu-Serum type I., Population: Caribbean; Bahamas.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H295R

Synonyms: NCI H295R, NCIH295R, H295R, H-295R, H295R-S1

Cross References: BTO:BTO_0002588, CLO:CLO_0008082, EFO:EFO_0002289, MCCL:MCC:0000355, ArrayExpress:E-MTAB-38, ATCC:CRL-2128, cancercellines:CVCL_0458, CCRID:1101HUM-PUMC000256, CCRID:5301HUM-KCB15009YJ, ChEMBL-Cells:ChEMBL3307998, ChEMBL-Targets:ChEMBL612593, CLS:300483, Cosmic:1172633, Cosmic:1191070, Cosmic:1622873, Cosmic:2364101, Cosmic:2574494, IGRhCellID:NCIH295R, KCB:KCB_2015009YJ, Lonza:378, Progenetix:CVCL_0458, PubChem_Cell_line:CVCL_0458, Wikidata:Q25323725

ID: CVCL_0458

Hierarchy: cvcl_0456

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260920T004616+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H295R.

No alerts have been found for NCI-H295R.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 296 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Shi X, et al. (2026) Proteomic profiling reveals novel insights into hypercortisolism adrenal adenomas. *Metabolism: clinical and experimental*, 183, 156691.

Hosseini A, et al. (2026) Roflumilast Enhances Liraglutide's Atrial Natriuretic Peptide-Dependent Suppression of Adrenal Aldosterone Secretion. *International journal of molecular sciences*, 27(9).

Schiavon A, et al. (2026) Targeting ER stress in adrenocortical carcinoma: Celastrol as a novel therapeutic candidate. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 197, 119156.

Triebig AS, et al. (2026) Glucocorticoids induce a phagocytic C1Q+ macrophage phenotype primed for IFN γ -dependent CXCL9 secretion. *Scientific reports*, 16(1).

Gebenlian JL, et al. (2026) The essential role of the redox balance in adrenal steroidogenesis. *Archives of endocrinology and metabolism*, 70(4).

Zou C, et al. (2025) Identification of CENPM as a key gene driving adrenocortical carcinoma metastasis via physical interaction with immune checkpoint ligand FGL1. *Clinical and translational medicine*, 15(1), e70182.

Nozza E, et al. (2025) Preclinical evaluation of the antitumoral efficacy of Wee1 inhibitor AZD1775 in adrenocortical carcinoma. *Pharmacological research*, 221, 107997.

Chan YS, et al. (2025) γ -catenin functions as a molecular adapter for disordered cBAF interactions. *Molecular cell*, 85(16), 3041.

Pramanik J, et al. (2025) Drug repurposing reveals posaconazole as a CYP11A1 inhibitor enhancing anti-tumor immunity. *iScience*, 28(5), 112488.

Catalano R, et al. (2025) Emerging role of IGF1R and IR expression and localisation in adrenocortical carcinomas. *Cell communication and signaling : CCS*, 23(1), 119.

Butz H, et al. (2025) Defactinib in Combination with Mitotane Can Be an Effective Treatment in Human Adrenocortical Carcinoma. *International journal of molecular sciences*, 26(13).

Fan Z, et al. (2024) Macrophages preserve endothelial cell specialization in the adrenal gland to modulate aldosterone secretion and blood pressure. *Cell reports*, 43(7), 114395.

Feely S, et al. (2024) Development and Characterization of 3-Dimensional Cell Culture Models of Adrenocortical Carcinoma. *Endocrinology*, 166(1).

Arakawa Y, et al. (2024) Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts. *Cancer research communications*, 4(3), 834.

Yang E, et al. (2023) Sfrp2 regulates the WNT/ β -catenin pathway to slow the development of aldosterone-producing adenoma. *Cardiovascular diagnosis and therapy*, 13(3), 523.

Parry CM, et al. (2023) Platelet-derived growth factor D expression in adrenal cells is modulated by corticosteroids: putative role in adrenal suppression. *Pediatric research*, 93(1), 97.

Fei L, et al. (2023) Carbonic anhydrases III and IX are new players in the crosstalk between adrenocortical carcinoma and its altered adipose microenvironment. *Journal of endocrinological investigation*, 46(7), 1449.

Tamburello M, et al. (2023) Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines. *International journal of molecular sciences*, 24(7).

Wu X, et al. (2023) Somatic mutations of *CADM1* in aldosterone-producing adenomas and gap junction-dependent regulation of aldosterone production. *Nature genetics*, 55(6), 1009.

Omar MH, et al. (2023) Proximity biotinylation to define the local environment of the protein kinase A catalytic subunit in adrenal cells. *STAR protocols*, 4(1), 101992.